

# From Code to Cure: Accelerating Oligonucleotide Design with AI

*An Advanced AI Platform for Rapid, Precise Engineering of Oligonucleotide Therapeutics*

SAN FRANCISCO , CA, UNITED STATES, December 12, 2025 /EINPresswire.com/ -- [Ainnocence](#), a California-based biotechnology company pioneering AI-native drug design is expanding nucleic

“

We convert years of discovery into hours of design, creating programmable, sequence-driven therapies for even the most elusive targets”

*Dr. Lurong Pan, CEO of Ainnocence*

acid engineering platform built to accelerate the discovery and optimization of mRNA, siRNA, antisense oligonucleotides (ASOs), aptamers and programmable RNA constructs. This next-generation system combines generative AI with large-scale molecular simulation, enabling developers to design safer, more stable and more precisely targeted oligonucleotide therapeutics.

Oligonucleotide engineering has traditionally been slowed by challenges in sequence selection, immunogenicity, durability, manufacturability, and delivery compatibility.

Ainnocence’s platform addresses these limitations through a sequence-first approach that evaluates millions to billions of candidates in silico, identifying the optimal therapeutic designs long before laboratory testing begins.

“We convert years of discovery into hours of design, creating programmable, sequence-driven therapies for even the most elusive targets” said Lurong Pan, PhD, Founder and CEO of Ainnocence. “[SenseAI](#) enables large-scale, rational engineering of oligonucleotide therapeutics with precision, speed and predictive reliability. The result is a path to therapies that once seemed unattainable.”

## Rewriting the Oligonucleotide Design Process

Ainnocence’s nucleic acid platform advances several core areas critical for therapeutic success:

- mRNA optimization that fine-tunes codon usage, UTRs, structural motifs, and expression efficiency to maximize stability and control immune signaling.
- siRNA and ASO design enhanced by off-target minimization, guide-strand tuning, and delivery-ready sequence architecture.

- Aptamer engineering using structural modeling and generative algorithms to identify high-affinity binders with improved stability and specificity.
- Delivery-aware modeling informed by compatibility with lipid nanoparticles and emerging delivery modalities.
- Ultrafast in silico screening that compresses years of trial-and-error sequence exploration into hours.
- A Unified Engine for Scalable, Experiment-Ready RNA and DNA Innovation

The nucleic acid platform is built to bridge computational prediction with real-world therapeutic development. Large-scale generative modeling works hand-in-hand with curated experimental datasets, allowing the system to learn from thousands of sequence–function relationships across mRNA, siRNA, ASOs and aptamers. This framework produces designs that are not only theoretically optimized but also aligned with manufacturability, delivery compatibility, and biological performance. The result is a streamlined path from digital sequence generation to lab-ready constructs that shorten discovery timelines while improving downstream success.

## Partner With Ainnocence

Ainnocence invites collaborations with academic laboratories, biopharmaceutical companies, and synthetic biology organizations seeking to accelerate discovery in mRNA, siRNA, ASO, aptamer, and nucleic acid engineering.

For partnership inquiries, email [service@ainnocence.com](mailto:service@ainnocence.com) or visit [www.ainnocence.com](http://www.ainnocence.com)

## About Ainnocence

Founded in 2021 and headquartered in California, Ainnocence is a next-generation biotechnology company transforming drug discovery and synthetic biology through AI-native, sequence-first engineering. The company's self-evolving platform evaluates up to  $10^{10}$  molecules spanning proteins, antibodies, small molecules, and nucleic acids within hours, enabling rapid, multi-objective therapeutic design. By reducing R&D timelines and costs while increasing success rates, Ainnocence empowers industry and academic partners to pursue bold innovations across medicine, sustainability, and biotechnology.

**SenseAI™**  
RNA Design Engine

**Design and Modification of therapeutic RNA** ▾

**Chemical Modification & Sequence Adjustment** ▾

- Modified Base Prediction
- Design of Subsidiary Units Such as Cap, polyA, and Dangling Bases

**mRNA Codon Optimization** ▾

- Flexible Selection of Constraints
- Multiple Optimization Strategies such as Prioritizing Expression or Maintaining Low Abundance Codon

**UTR Component Annotations & Modifications** ▾

- Insertion, Mutation, and Deletion of UTR Components
- Design High Expression UTR from Scratch

**siRNA Design & Optimization** ▾

- Inhibition Efficiency Evaluation
- Specificity Evaluation

**Application Scenarios**

- mRNA Vaccine
- mRNA Based Protein Replacement Therapy
- siRNA Drugs

**Why Choose Ainnocence?**

- 1 Comprehensive genome screening
- 2 Wet lab validated
- 3 Ultra-High Throughput
- 4 Rapid Turnaround: from a few hours to two weeks

COPYRIGHT © 2025 INNOCENCE INC. ALL RIGHTS RESERVED. [service@ainnocence.com](mailto:service@ainnocence.com) +1 202 249 7424 [www.ainnocence.com](http://www.ainnocence.com)

Ainnocence's SenseAI Platform for AI-driven, sequence-based nucleic acid engineering, enabling rapid in silico design, sequence optimization and predictive modeling.

Lurong Pan, PhD  
Ainnocence  
+1 205-249-7424  
service@ainnocence.com  
Visit us on social media:  
[LinkedIn](#)  
[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/874463882>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.